论文部分内容阅读
不久前,非官方的国际制药 企业协会联合会(IFP- MA)发表了《鼓励中国的新药研发》专题研究报告,报告指出:中国不仅已经是世界仿制性药物生产的大国,而且很快将成为创新性药物研发的大国。该报告在“政府重视程度”、“知识产权保护”、“基础设施”、“现有产业”、“人力资源”等5个新药研发绝对必要条件的评估上,中国的得分是,前三项超过4分,后两项超过3分,被认为是最适合参与全球药品创新的发展中国家。
Not long ago, the unofficial International Pharmaceutical Manufacturers Association (IFP-MA) published a special study entitled “Encouraging China’s R & D of new drugs”. The report pointed out: Not only China is already a large country in the world in the production of generic drugs, but will soon become Innovative drug development of the big country. The report scores on the absolute necessary conditions for research and development of five new drugs, namely “government’s emphasis,” “intellectual property protection,” “infrastructure,” “existing industries, and” human resources. More than 4 points, the latter two more than 3 points, is considered to be the most suitable for participation in global drug innovation in developing countries.